PNC Financial Services Group Inc. Boosts Stake in DaVita Inc. $DVA

PNC Financial Services Group Inc. grew its stake in DaVita Inc. (NYSE:DVA) by 4.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,831 shares of the company’s stock after acquiring an additional 558 shares during the quarter. PNC Financial Services Group Inc.’s holdings in DaVita were worth $1,970,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Invesco Ltd. boosted its position in DaVita by 3.4% during the first quarter. Invesco Ltd. now owns 1,642,947 shares of the company’s stock valued at $251,322,000 after purchasing an additional 53,402 shares in the last quarter. Northern Trust Corp lifted its position in shares of DaVita by 20.2% during the first quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock valued at $136,240,000 after buying an additional 149,858 shares during the last quarter. Gates Capital Management Inc. boosted its holdings in shares of DaVita by 0.7% in the 1st quarter. Gates Capital Management Inc. now owns 722,205 shares of the company’s stock valued at $110,476,000 after buying an additional 4,698 shares in the last quarter. Amundi grew its position in shares of DaVita by 16.0% in the 1st quarter. Amundi now owns 517,690 shares of the company’s stock worth $79,584,000 after buying an additional 71,304 shares during the last quarter. Finally, Epoch Investment Partners Inc. raised its stake in shares of DaVita by 10.7% during the 1st quarter. Epoch Investment Partners Inc. now owns 407,921 shares of the company’s stock worth $62,400,000 after acquiring an additional 39,485 shares in the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have issued reports on DVA shares. Cowen reaffirmed a “hold” rating on shares of DaVita in a report on Monday, November 3rd. Truist Financial set a $140.00 target price on DaVita in a research note on Tuesday, October 14th. Zacks Research cut DaVita from a “hold” rating to a “strong sell” rating in a research note on Thursday, October 30th. Wall Street Zen lowered DaVita from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Finally, Barclays decreased their price objective on shares of DaVita from $149.00 to $143.00 and set an “equal weight” rating for the company in a research report on Thursday, October 30th. Five analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $148.00.

DaVita Stock Performance

DaVita stock opened at $116.70 on Wednesday. DaVita Inc. has a fifty-two week low of $115.39 and a fifty-two week high of $179.60. The company has a market cap of $8.24 billion, a PE ratio of 12.02, a PEG ratio of 0.91 and a beta of 1.13. The business’s 50-day simple moving average is $126.94 and its two-hundred day simple moving average is $134.99.

DaVita (NYSE:DVA) last released its earnings results on Wednesday, October 29th. The company reported $2.51 EPS for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). DaVita had a return on equity of 815.62% and a net margin of 5.80%.The firm had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.43 billion. During the same period last year, the firm earned $2.59 EPS. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. As a group, analysts predict that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.